Search

Your search keyword '"Theocharis AD"' showing total 36 results

Search Constraints

Start Over You searched for: Author "Theocharis AD" Remove constraint Author: "Theocharis AD" Search Limiters Full Text Remove constraint Search Limiters: Full Text
36 results on '"Theocharis AD"'

Search Results

1. New Esters of Ferrediol and Sideritriol in Sideritis clandestina subsp. peloponnesiaca : Characterization and Antiproliferative Activity.

2. The Expression of Serglycin Is Required for Active Transforming Growth Factor β Receptor I Tumorigenic Signaling in Glioblastoma Cells and Paracrine Activation of Stromal Fibroblasts via CXCR-2.

3. Resistance to hormone therapy in breast cancer cells promotes autophagy and EGFR signaling pathway.

4. Proteoglycans Determine the Dynamic Landscape of EMT and Cancer Cell Stemness.

5. Synthesis and Antiproliferative Activity of Novel Dehydroabietic Acid-Chalcone Hybrids.

6. Serglycin Is Involved in TGF-β Induced Epithelial-Mesenchymal Transition and Is Highly Expressed by Immune Cells in Breast Cancer Tissue.

7. A guide to the composition and functions of the extracellular matrix.

8. Complexity of matrix phenotypes.

9. Serglycin activates pro-tumorigenic signaling and controls glioblastoma cell stemness, differentiation and invasive potential.

10. The extracellular matrix as a multitasking player in disease.

11. IGF-IR cooperates with ERα to inhibit breast cancer cell aggressiveness by regulating the expression and localisation of ECM molecules.

12. Syndecans - key regulators of cell signaling and biological functions.

13. Epidermal growth factor receptor status and Notch inhibition in non-small cell lung cancer cells.

14. Estrogen receptor alpha mediates epithelial to mesenchymal transition, expression of specific matrix effectors and functional properties of breast cancer cells.

15. ADAMTS expression in colorectal cancer.

16. Increased Expression of Serglycin in Specific Carcinomas and Aggressive Cancer Cell Lines.

17. Cell-matrix interactions: focus on proteoglycan-proteinase interplay and pharmacological targeting in cancer.

18. Syndecans as modulators and potential pharmacological targets in cancer progression.

19. Serglycin: at the crossroad of inflammation and malignancy.

20. Serglycin is implicated in the promotion of aggressive phenotype of breast cancer cells.

21. Efficient TGFβ-induced epithelial-mesenchymal transition depends on hyaluronan synthase HAS2.

22. In vitro reconstitution of complexes between pro-matrix metalloproteinase-9 and the proteoglycans serglycin and versican.

23. Cell-surface serglycin promotes adhesion of myeloma cells to collagen type I and affects the expression of matrix metalloproteinases.

24. Evaluation of the coordinated actions of estrogen receptors with epidermal growth factor receptor and insulin-like growth factor receptor in the expression of cell surface heparan sulfate proteoglycans and cell motility in breast cancer cells.

25. Imatinib as a key inhibitor of the platelet-derived growth factor receptor mediated expression of cell surface heparan sulfate proteoglycans and functional properties of breast cancer cells.

26. Expression of syndecan-4 and correlation with metastatic potential in testicular germ cell tumours.

28. Glycosaminoglycans: key players in cancer cell biology and treatment.

29. Versican but not decorin accumulation is related to malignancy in mammographically detected high density and malignant-appearing microcalcifications in non-palpable breast carcinomas.

30. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting.

31. Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting.

32. Estradiol-estrogen receptor: a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells.

33. The biological role of chondroitin sulfate in cancer and chondroitin-based anticancer agents.

34. Serglycin constitutively secreted by myeloma plasma cells is a potent inhibitor of bone mineralization in vitro.

35. Expression of MMPs and TIMPs genes in human breast cancer epithelial cells depends on cell culture conditions and is associated with their invasive potential.

36. STI571 as a potent inhibitor of growth and invasiveness of human epithelial breast cancer cells.

Catalog

Books, media, physical & digital resources